Cardiac Contraindications and Risks of Initiating Trastuzumab When Baseline LVEF Is Low

Eligibility Criteria from Pivotal Trials

• The pivotal adjuvant trastuzumab trials required a normal baseline left‑ventricular ejection fraction (LVEF) for enrollment, excluding any patient with significant baseline cardiac dysfunction (e.g., LVEF ≈ 34%). 1
• In those trials, treatment was withheld if an absolute LVEF decline of ≥ 10 percentage points fell below the lower limit of normal, and also if the decline reached ≥ 16 percentage points from baseline. 1

Cardiotoxicity Incidence Observed in Clinical Studies

• When trastuzumab was combined with anthracyclines, ≈ 27 % of patients developed symptomatic or asymptomatic LV dysfunction. 1
• In early metastatic‑setting trials, ≈ 16 % experienced NYHA class III–IV heart failure. 1
• Even with sequential (non‑concurrent) anthracycline administration, 7.1 %–18.6 % of patients in adjuvant trials showed a clinically significant LVEF decline. 1

Risk Associated With Very Low Baseline LVEF

• A baseline LVEF of 34 % represents moderate‑to‑severe systolic dysfunction and confers a substantially elevated risk of progression to severe heart failure compared with patients who have normal LVEF. 1

Mechanistic Evidence (American College of Cardiology)

• HER2 signaling is essential for cardiomyocyte survival; HER2 blockade in the heart impairs cardiomyocyte viability, predisposing to dysfunction. 2
• In murine models, HER2 deficiency produces dilated cardiomyopathy and markedly increases sensitivity to doxorubicin‑induced injury. 2

Alternative HER2‑Targeted Options With Lower Cardiac Risk

• The HER2‑directed agent pertuzumab has been shown to have cardiac event rates comparable to control arms, suggesting a lower intrinsic cardiotoxicity profile relative to trastuzumab. 2

Monitoring Recommendations Derived From Trial Protocols

• Protocols from the pivotal trials mandated serial LVEF assessments every 3 months for patients receiving trastuzumab to detect early declines. 1